Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

This is a prospective, multi-cohort, exploratory clinical study designed to evaluate the efficacy and safety of neoadjuvant adebrelimab combined with chemotherapy in patients with resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), with a particular focus on the effect of the time-of-day of immunotherapy infusion. Eligible patients with histologically or cytologically confirmed, resectable locally advanced thoracic ESCC will be randomly assigned in a 1:1:1 ratio to three cohorts according to predefined immunotherapy infusion time windows. Cohort A will receive adeb

Trial Details

NCT ID
NCT07452601
Phase
PHASE2
Sponsor
Tang-Du Hospital
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • Adebrelimab plus nab-paclitaxel and cisplatin
Locations (sample)
  • Xi'an, Shannxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Patients who have signed a written informed consent form and voluntarily agree to participate in the study.
  • Histologically or cytologically confirmed esophageal squamous cell carcinoma.
  • Tumor located in the thoracic esophagus, assessed by CT, MRI, EUS, or other imaging modalities, with clinical stage T1b-4aN+M0 or T2-4N0M0 (T2N0 pa…
  • Tumors deemed potentially resectable with R0 margins.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →